Are the contents of treatment outcomes in fibromyalgia trials represented in the international classification of functioning, disability, and health?

Clinical Journal of Pain

Volumn 23, Issue 8, 2007, Pages 691-701

  Offenbächer, Martin ^a   Cieza, Alarcos ^a   Brockow, Thomas ^b   Amann, Edda ^a   Kollerits, Barbara ^a   Stucki, Gerold ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Spa Medicine Research Institute ^*

Author keywords

Chronic wide spread pain; Content analysis; Fibromyalgia; ICF; Outcome assessment; Systematic review

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALPHA INTERFERON; ALPRAZOLAM; AMITRIPTYLINE; BROMAZEPAM; CALCITONIN; CHLORMEZANONE; CITALOPRAM; CYCLOBENZAPRINE; FLUOXETINE; FLUPENTIXOL; GROWTH HORMONE; IBUPROFEN; MALIC ACID; PHENINDIONE; PLACEBO; RITANSERIN; S ADENOSYLMETHIONINE; TENOXICAM; TRAMADOL; TRAZODONE; ZOLPIDEM; ZOPICLONE;

ACUPUNCTURE; ARTICLE; CONTENT ANALYSIS; DISEASE CLASSIFICATION; FIBROMYALGIA; HEALTH STATUS; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MEDLINE; OUTCOME ASSESSMENT; PHOTOTHERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; TIME SERIES ANALYSIS;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; FIBROMYALGIA; HEALTH STATUS; HUMANS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; REFERENCE STANDARDS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 34648843137     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318148b93d     Document Type: Article

References (99)

1. Buskila D, Abramov G, Biton A, et al. The prevalence of pain complaints in a general population in Israel and its implications for utilization of health services. J Rheumatol. 2000;27:1521-1525.
2. Bergman S, Herrstrom P, Hogstrom K, et al. Chronic musculoskeletal pain, prevalence rates, and sociodemographic associations in a Swedish population study. J Rheumatol. 2001;28:1369-1377.
3. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
4. White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999;26:1570-1576.
5. Cousins MJ. Foreword. In: Back Pain in the Workplace Management of Disability in Nonspecific Conditions Task Force Report. FordyceWE, ed. Seattle: IASP Press; 1995.
6. Wolfe F, Ross K, Anderson J, et al. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22:151-156.
7. Bou-Holaigah I, Calkins H, Flynn JA, et al. Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol. 1997;15:239-246.
8. Landro NI, Stiles TC, Sletvold H. Memory functioning in patients with primary fibromyalgia and major depression and healthy controls. J Psychosom Res. 1997;42:297-306.
9. Bennett RM. The contribution of muscle to the generation of fibromyalgia symptomatology. J Musculoskel Pain. 1996;4:35-59.
10. Kerr S, Fairbrother G, Crawford M, et al. Patient characteristics and quality of life among a sample of Australian chronic pain clinic attendees. Intern Med J. 2004;34:403-409.
11. White KP, Speechley M, Harth M, et al. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum. 1999;42:76-83.
12. Neumann L, Berzak A, Buskila D. Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). Semin Arthritis Rheum. 2000;29:400-408.
13. Burckhardt CS, Clark SR, O'Reilly CA, et al. Pain-coping strategies of women with fibromyalgia: relationship to pain, fatigue, and quality of life. J Musculoskel Pain. 1997;5:5-21.
14. Bolwijn PH, van Santen-Hoeufft MH, Baars HM, et al. The social network characteristics of fibromyalgia patients compared with healthy controls. Arthritis Care Res. 1996;9:18-26.
15. Ferrari R. The biopsychosocial model - a tool for rheumatologists. Baill Clin Rheumatol. 2000;14:787-795.
16. World Health Organization. International Classification of Functioning, D.a.H.I.W., 2001.
17. Wolfe F, Lassere M, van der Heijde D, et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999;26:484-489.
18. Stucki G, Boonen A, Tugwell P, et al. The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. J Rheumatol. 2007;34:600-606.
19. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309:1286-1291.
20. Cieza A, Brockow T, Ewert T, et al. Linking health-status measurements to the international classification of functioning, disability and health. J Rehabil Med. 2002;34:205-210.
21. Drewes AM, Andreasen A, Jennum P, et al. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol. 1991;20:288-293.
22. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral Sadenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. 1991;20:294-302.
23. Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 1991;18:452-454.
24. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23:255-259.
25. Pattrick M, Swannell A, Doherty M. Chlormezanone in primary fibromyalgia syndrome: a double blind placebo controlled study. Br J Rheumatol. 1993;32:55-58.
26. Gronblad M, Nykanen J, Konttinen Y, et al. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol. 1993;12:186-191.
27. Santandrea S, Montrone F, Sarzi-Puttini P, et al. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res. 1993;21:74-80.
28. Volkmann H, Norregaard J, Jacobsen S, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol. 1997;26:206-211.
29. Moldofsky H, Lue FA, Mously C, et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol. 1996;23:529-533.
30. Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum. 1995;38:1211-1217.
31. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445-449.
32. Russell IJ, Michalek JE, Flechas JD, et al. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. 1995;22:953-958.
33. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4:27-35.
34. Russell IJ, Michalek JE, Kang YK, et al. Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-alpha. J Interferon Cytokine Res. 1999;19:961-968.
35. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998;104:227-231.
36. Bessette L, Carette S, Fossel AH, et al. A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol. 1998;27:112-116.
37. Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res. 1998;18:13-19.
38. Olin R, Klein R, Berg PA. A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids. Clin Rheumatol. 1998;17:89-94.
39. Fossaluzza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharmacol Res. 1992;12:99-102.
40. Zitman FG, Linssen AC, Edelbroek PM, et al. Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder? Pain. 1991;47:25-30.
41. Van Kempen GM, Zitman FG, Linssen AC, et al. Biochemical measures in patients with a somatoform pain disorder, before, during, and after treatment with amitriptyline with or without flupentixol. Biol Psychiatry. 1992;31:670-680.
42. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37:32-40.
43. Bellometti S, Galzigna L. Function of the hypothalamic adrenal axis in patients with fibromyalgia syndrome undergoing mud-pack treatment. Int J Clin Pharmacol Res. 1999;19:27-33.
44. Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998;37:1279-1286.
45. Kempenaers C, Simenon G, Vander Elst M, et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology. 1994;30:66-72.
46. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, doubleblind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-1859.
47. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain. 1996;65:221-225.
48. Russell IJ, Fletcher EM, Michalek JE, et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum. 1991;34:552-560.
49. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol. 1996;398:373-379.
50. Deluze C, Bosia L, Zirbs A, et al. Electroacupuncture in fibromyalgia: results of a controlled trial. BMJ. 1992;305:1249-1252.
51. Haanen HC, Hoenderdos HT, van Romunde LK, et al. Controlled trial of hypnotherapy in the treatment of refractory fibromyalgia. J Rheumatol. 1991;18:72-75.
52. Blunt KL, Rajwani MH, Guerriero RC. The effectiveness of chiropractic management of fibromyalgia patients: a pilot study. J Manipulative Physiol Ther. 1997;20:389-399.
53. Pearl SJ, Lue F, MacLean AW, et al. The effects of bright light treatment on the symptoms of fibromyalgia. J Rheumatol. 1996;23:896-902.
54. Martin L, Nutting A, MacIntosh BR, et al. An exercise program in the treatment of fibromyalgia. J Rheumatol. 1996;23:1050-1053.
55. Vlaeyen JW, Teeken-Gruben NJ, Goossens ME, et al. Cognitiveeducational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. J Rheumatol. 1996;23:1237-1245.
56. Ramsay C, Moreland J, Ho M, et al. An observer-blinded comparison of supervised and unsupervised aerobic exercise regimens in fibromyalgia. Rheumatology (Oxford). 2000;39:501-505.
57. Gowans SE, deHueck A, Voss S, et al. A randomized, controlled trial of exercise and education for individuals with fibromyalgia. Arthritis Care Res. 1999;12:120-128.
58. Keel PJ, Bodoky C, Gerhard U, et al. Comparison of integrated group therapy and group relaxation training for fibromyalgia. Clin J Pain. 1998;14:232-238.
59. Burckhardt CS, Mannerkorpi K, Hedenberg L, et al. A randomized, controlled clinical trial of education and physical training for women with fibromyalgia. J Rheumatol. 1994;21:714-720.
60. Wigers SH, Stiles TC, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol. 1996;25:77-86.
61. Bakker C, Rutten M, van Santen-Hoeufft M, et al. Patient utilities in fibromyalgia and the association with other outcome measures. J Rheumatol. 1995;22:1536-1543.
62. Buckelew SP, Conway R, Parker J, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Care Res. 1998;11:196-209.
63. Hudson JI, Goldenberg DL, Pope HG, et al. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med. 1992;92:363-367.
64. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med. 2004;66:837-844.
65. Uveges JM, Parker JC, Smarr KL, et al. Psychological symptoms in primary fibromyalgia syndrome: relationship to pain, life stress, and sleep disturbance. Arthritis Rheum. 1990;33:1279-1283.
66. Offenbaecher M, Glatzeder K, Ackenheil M. Self-reported depression, familial history of depression and fibromyalgia (FM), and psychological distress in patients with FM. Z Rheumatol. 1998;57(suppl 2):94-96.
67. Henriksson C, Gundmark I, Bengtsson A, et al. Living with fibromyalgia. Consequences for everyday life. Clin J Pain. 1992;8:138-144.
68. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol. 1993;20:475-479.
69. Stucki G, Ewert T, Cieza A. Value and application of the ICF in rehabilitation medicine. Disabil Rehabil. 2003;25:628-634.
70. Penrod JR, Bernatsky S, Adam V, et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol. 2004;31:1391-1398.
71. Oliver K, Cronan TA, Walen HR, et al. Effects of social support and education on health care costs for patients with fibromyalgia. J Rheumatol. 2001;28:2711-2719.
72. Walen HR, Cronan PA, Bigatti SM. Factors associated with healthcare costs in women with fibromyalgia. Am J Manag Care. 2001;7(Spec No):SP39-SP47.
73. Blalock SJ, DeVellis RF, Brown GK, et al. Validity of the Center for Epidemiological Studies Depression Scale in arthritis populations. Arthritis Rheum. 1989;32:991-997.
74. Lorig K, Chastain RL, Ung E, et al. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum. 1989;32:37-44.
75. Arslan S, Yunus MB, Aldag JC. Fibromyalgia in rheumatoid arthritis. Arthritis Rheum. 2001;44:S71.
76. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum. 1994;37:1181-1188.
77. Martin MY, Bradley LA, Alexander RW, et al. Coping strategies predict disability in patients with primary fibromyalgia. Pain. 1996;68:45-53.
78. Hassett AL, Cone JD, Patella SJ, et al. The role of catastrophizing in the pain and depression of women with fibromyalgia syndrome. Arthritis Rheum. 2000;43:2493-2500.
79. Gaston-Johansson F, GustafssonM, Felldin R, et al. A comparative study of feelings, attitudes and behaviors of patients with fibromyalgia and rheumatoid arthritis. Soc Sci Med. 1990;31:941-947.
80. Fransen J, Stucki G. Current use of health status instruments in randomised controlled trials on patients with rheumatoid arthritis. Dis Manage Health Outcomes. 1998;3:271-277.
81. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337-345.
82. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9-19.
83. McQuay H. Consensus on outcome measures for chronic pain trials. Pain. 2005;113:1-2.
84. Wolfe F, Pincus T, Thompson AK, et al. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Rheum. 2003;49:59-63.
85. Russak SM, Croft JD Jr, Furst DE, et al. The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Rheum. 2003;49:574-584.
86. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol. 2005;32:575-577.
87. Linden A, Roberts N. A user's guide to the disease management literature: recommendations for reporting and assessing program outcomes. Am J Manage Care. 2005;11:113-120.
88. Turk DC, Dworkin RH. What should be the core outcomes in chronic pain clinical trials? Arthritis Res Ther. 2004;6:151-154.
89. Yazici Y. Monitoring outcomes of arthritis and longitudinal data collection using patient questionnaires in routine care. Bull Hosp Jt Dis. 2006;64:40-44.
90. Testa MA. Interpretation of quality-of-life outcomes: issues that affect magnitude and meaning. Med Care. 2000;38(9 suppl):II166-II174.
91. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol. 2005;32:2270-2277.
92. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395.
93. Turk DC, Okifuji A, Sinclair JD, et al. Differential responses by psychosocial subgroups of fibromyalgia syndrome patients to an interdisciplinary treatment. Arthritis Care Res. 1998;11:397-404.
94. Thieme K, Spies C, Sinha P, et al. Predictors of pain behaviors in fibromyalgia syndrome. Arthritis Rheum. 2005;53:343-350.
95. Sigl T, Cieza A, Brockow T, et al. Content comparison of low back pain-specific measures based on the International Classification of Functioning, Disability and Health (ICF). Clin J Pain. 2006;22:147-153.
96. Cieza A, Stucki G. Content comparison of health-related quality of life (HRQOL) instruments based on the international classification of functioning, disability and health (ICF). Qual Life Res. 2005;14:1225-1237.
97. Juniper EF, Price DB, Stampone PA, et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest. 2002;121:1824-1832.
98. Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med. 2001;163:924-929.
99. Conners AF. The transformation oft medicine: the role of outcomes research. Obes Res. 2002;10(suppl 1):S3-S5.